Aquestive Therapeutics, Inc. (AQST) News
Follow Aquestive Therapeutics, Inc. (AQST) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Aquestive Therapeutics Forecasts 2026 Revenue of $46 Million–$50 Million
EARNINGS | Nov 04, 2026, 02:19 PM UTC
M
Aquestive Therapeutics Q3 2026 Revenue Falls to $7.6 Million
EQUITY | Nov 03, 2026, 10:14 PM UTC
M
Aquestive Therapeutics Reports Quarterly Results for Period Ended September 30
Aquestive Therapeutics reported results for the quarter ended September 30. The supplied text contains no financial figures.
EQUITY | Nov 03, 2026, 10:13 PM UTC
M
Aquestive Therapeutics Reports Third-Quarter 2026 Financial Results and Business Update
EQUITY | Nov 03, 2026, 09:23 PM UTC
M
Aquestive Therapeutics Q3 earnings snapshot
EQUITY | Nov 03, 2026, 09:16 PM UTC
M
Aquestive Therapeutics Sets November 3 Q3 Results Release and November 4 Call
Aquestive Therapeutics plans to report third-quarter 2026 financial results and business highlights on November 3, followed by a conference call on November 4 at 8:00 a.m. ET.
EQUITY | Oct 27, 2026, 11:03 AM UTC
L
FDA accepts Aquestive Therapeutics’ Anaphylm NDA resubmission
The FDA set a PDUFA goal date of March 16, 2027.
REGULATION | Oct 15, 2026, 11:00 AM UTC
M
Aquestive Licenses U.S. Libervant Rights to Eton for Up to $47.5M
Aquestive granted Eton exclusive U.S. commercialization rights to Libervant, a diazepam buccal film for acute treatment of seizure clusters, subject to FDA approvals. The agreement includes $10 million upfront and up to
MNA | Oct 14, 2026, 11:23 AM UTC
L
Aquestive Therapeutics elects Richard J. Daly to its Board as Class I director
Aquestive Therapeutics elected Richard J. Daly to its Board as a Class I director, effective October 14, 2026.Original SEC Filing: Aquestive Therapeutics, Inc. [ AQST ] - 8-K - Sep. 29, 2026This is an AI-powered summary.
REGULATION | Sep 29, 2026, 11:23 AM UTC
L
Aquestive Therapeutics, Inc. (AQST) Appoints Richard Daly to Board
Aquestive Therapeutics appointed Rich Daly to its Board of Directors, effective Oct. 14, 2026. The board will have eight directors, seven independent.Material DetailsContext by AI AnalystAquestive is in a pre-commercial
REGULATION | Sep 29, 2026, 11:09 AM UTC
L
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors
NEWS | Sep 29, 2026, 11:09 AM UTC
L
Aquestive Therapeutics posts investor presentation; NDA resubmission for Anaphylm, $98.5M cash
Aquestive Therapeutics disclosed an investor presentation detailing an NDA resubmission for Anaphylm and its cash runway of $98.5 million.Key Highlights:Original SEC Filing: Aquestive Therapeutics, Inc. [ AQST ] - 8-K -
REGULATION | Sep 25, 2026, 12:05 PM UTC
M
Aquestive Therapeutics resubmits NDA for Anaphylm
The company said it resubmitted its New Drug Application for Anaphylm after supportive human factors and pharmacokinetic study results.
EQUITY | Sep 17, 2026, 11:14 AM UTC
L
AQST - Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
AQST - Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
REGULATION | Sep 17, 2026, 11:00 AM UTC
L
AQST: Anaphylm's rapid, user-friendly delivery and strong clinical profile position it for major market impact
Anaphylm, a sublingual film for severe allergic reactions, is poised for FDA resubmission with improved packaging and strong clinical data showing rapid onset and robust efficacy. The company is launch-ready with secured
REGULATION | Sep 09, 2026, 08:11 PM UTC
L
Aquestive Therapeutics to participate in upcoming September investor conferences
Aquestive Therapeutics said it will participate in upcoming September investor conferences.
EQUITY | Sep 01, 2026, 11:08 AM UTC
L
AQST - Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
AQST - Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
Aquestive Therapeutics Reports Earnings Miss
Aquestive Therapeutics reports EPS miss by 8c, revenue beat
EARNINGS | Aug 11, 2026, 08:03 PM UTC
L
Aquestive Therapeutics Q2 EPS $(0.18) Misses $(0.12) Estimate, Sales $13.819M Beat $11.418M Estimate
Aquestive Therapeutics Q2 EPS $(0.18) Misses $(0.12) Estimate, Sales $13.819M Beat $11.418M Estimate
EARNINGS | Aug 11, 2026, 08:01 PM UTC
L
AQST - Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
AQST - Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 11, 2026, 08:01 PM UTC
L
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M Est
Aquestive Therapeutics (NASDAQ: AQST ) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $50.584 million estimate.
EARNINGS | Aug 11, 2026, 08:01 PM UTC
L
AQST - Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conferenc
AQST - Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
EARNINGS | Jul 29, 2026, 11:00 AM UTC